Japanese and Taiwanese shares recovered on Monday after last week’s AI-driven sell-off, but South Korea’s reversal highlighted fragile investor confidence.
Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1 clinical trial initiation planned for
REDWOOD CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies
F45 Training and FS8 invites entrepreneurs to commit before year-end, following strong Q3 studio openings and F45’s launch in Colombia, its 58th country F45 Training F45 Training Austin, TX, Nov. 04, 2026
Healthcare Data and Analytics Organization Hires Head of AI and Promotes New Chief Product Officer FRAMINGHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), a provider of healthcare data
FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members
VERO BEACH, FL, Nov. 04, 2026 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the
Preliminary Results Indicate Election of Two Company Nominees and Three DGB Nominees DANBURY, CT, Nov. 04, 2026 (GLOBE NEWSWIRE) — Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD), a
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Electra Therapeutics, Inc. (NASDAQ: ETRA) a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment
Internationally recognized certification validates ROC’s information security management system and controls, which can help streamline security reviews and compliance checks for buyers in highly regulated markets DENVER, CO, Nov. 04, 2026 (GLOBE
Follow